Olivia Vizier

Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.

In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.

AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.

Cardiff’s onvansertib is being trialed in a phase 1b/2 study in patients with metastatic colorectal cancer who have a mutation of the KRAS gene, according to a Wednesday release. The therapy is being combined with chemotherapy and Roche’s stalwart Avastin. Patients must have failed on chemotherapy and or/Avastin prior to entry in the trial.

Dorigo is principal investigator of a clinical trial of a new immunotherapy called maveropepimut-S. It’s being developed by IMV Inc., a pharmaceutical company focused on innovative immune cell activating approaches.

At the heart of Araris’ platform is its proprietary line of indication-specific peptide linkers with finely tuned hydrophilicity to accommodate various payloads, composed from an enzyme that’s already been approved by the FDA for food use. A native glycosylated antibody, the Araris linker with the payload, bind to form the ADC under the catalyzing effect

With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player focused around neuroscience could now add even more bite to Lilly’s bark.

“It’s not exactly rocket science,” Ludek Sojka, CTO, SOTIO, admitted during our conversation on managing raw material supplier relationships to better control overall C&G therapy COGS. However, the past year has proven that securing a reliable supply of raw materials will — despite our best intentions — always be an evergreen challenge. A great reminder

What it means to age is changing, and William Greene, M.D., CEO of Fountain Therapeutics, is one of those driving the change. Rather than focusing primarily on lifespan, he and his company are focusing on healthspan, and in particular, the impact of chronic degenerative diseases. The goal is to restore cellular resilience.

Clene Nanomedicine has quadrupled production capacity to support candidate CNM-Au8, a gold nanocrystal suspension it says could be a gamechanger in the neurodegenerative disease space.

AltruBio is a private company developing checkpoint-regulator monoclonal antibodies (mAbs) for treating immune disorders. The company uses its checkpoint regulators in a way it believes down-modulates overactivated

North Carolina-based Heat Biologics is also taking a proactive stance against potential pandemic threats. This week, the company established its Biothreat Advisory Board. Heat Chief Executive Officer Jeff Wolf said the board was created to support its biosecurity/biodefense initiative, which was originally conceived as a result of the ongoing pandemic.

BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.

BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.

Windree Therapeutics CEO and President Craig Fraser discusses the unmet needs in acute care, Windtree’s pipeline, the importance of Fast Track designations, and how his past military career primed him for success as a pharma leader.

In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company’s lead candidate, RAIN-32.

In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of ‘1104 and discuss the plan of the company’s clinical studies.

FDA-approved in June 2021, this new drug is great news for people prone to yeast infections.

Clene Nanomedicine has signed a pair of leases that will effectively quadruple its physical footprint in Cecil County. The company also plans to add about 400 new jobs in the area over the next five years.

Heat’s pipeline features candidates for immuno-oncology, infectious diseases and Covid-19. HS-110 has completed its Phase II trial to treat non-small cell lung cancer, and solid tumor treatment PTX-35 and T cell activator HS-130 are in Phase I trials. The new Scorpion site will support new drugs from discovery through clinical trials.

When Kristen Oelschlager, RN, chief operating officer at Castle Biosciences, learned about her cancer diagnosis, she was shocked. What she thought was a simple spot on her left temple turned out to be melanoma, a type of skin cancer that can lead to death, according to the National Cancer Institute. Melanoma of the skin accounts for 5.6% of

CNM-Au8, Clene’s lead drug candidate, is an aqueous suspension comprising catalytically active, clean-surfaced and faceted gold nanocrystals. The company explained in a statement that the therapy’s catalytically active nanocrystals fuel “critical cellular energy” that ultimately produce brain reactions enabling neurorepair and remyelination. This is reportedly accomplished via increases in neuronal and glial resilience to stressors

Boston-based PepGen’s lead candidate is a therapeutic oligonucleotide that targets exon 51 to treat a subset of DMD patients, putting the biotech squarely on the turf of Sarepta. Like Exondys 51, the drug is designed to mask exon 51 and thereby enable patients to produce the functional dystrophin needed to strengthen muscle fibers.

“We believe the synergy between Celularity’s placental-derived cells and our OnCARlytic platform has the potential to shift the cellular medicine paradigm,” Leslie Chong, managing director and chief executive officer of Imugene, stated in a press release.

Dr. Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study of ARO-AAT, an RNA therapeutic being co-developed by the company and Takeda, in patients with liver disease caused by alpha-1 antitrypsin deficiency (AATD).   He also talks about the company’s RNAi platform.